Skip to main content

Table 4 Indices of glucose metabolism at baseline and after 12 weeks of treatment

From: Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes

 

Baseline

12 weeks

P value

FPG, mg/dL

   

 Rosuva/Eze 2.5/10 mg

131 ± 25

135 ± 30

0.278

 Rosuva 5 mg

126 ± 21

125 ± 22

0.848

Fasting serum insulin, μ U/mL

   

 Rosuva/Eze 2.5/10 mg

8.5 ± 6.9

8.3 ± 6.0

0.435

 Rosuva 5 mg

9.1 ± 9.2

9.8 ± 11.0

0.128

HOMA-IR

   

 Rosuva/Eze 2.5/10 mg

2.8 ± 2.4

2.8 ± 2.4

0.983

 Rosuva 5 mg

2.7 ± 2.4

3.0 ± 3.0

0.162

HOMA-B

   

 Rosuva/Eze 2.5/10 mg

48 ± 38

45 ± 26

0.412

 Rosuva 5 mg

62 ± 94

68 ± 97

0.130

HbA1c,%

   

 Rosuva/Eze 2.5/10 mg

6.7 ± 0.6

6.8 ± 0.7

0.103

 Rosuva 5 mg

6.9 ± 0.7

6.9 ± 0.8

0.907

  1. Data are mean ± SD.
  2. Rosuva Rosuvastatin, Eze Ezetimibe, FPG Fasting plasma glucose, HOMA-IR Homeostasis model assessment of insulin resistance, HOMA-B HOMA of β-cell function.
  3. There were no significant differences among each baseline values.
  4. P values are for differences between baseline with 12 week.
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X